Skip to main content

EOFY

Save lives from heart disease with a tax-deductible donation today

Donate now

Our ongoing studies have successfully developed a novel in vivo model of thrombolysis (iCAT) that for the first time allows us the ability to examine the efficacy of novel drugs including novel thrombin inhibitors to facilitate clot lysis (recanalization), restore perfusion in the brain, as well as determine whether cerebral damage and cognitive impairment associated with stroke are reduced. We are using this model to assess the efficacy of currently approved and novel anticlotting agents to facilitate stroke treatment.

Donate today to save lives

Donate now